TP53 in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDSs) are heterogeneous for their morphology, clinical characteristics, survival of patients, and evolution to acute myeloid leukemia. Different prognostic scoring systems including the International Prognostic Scoring System (IPSS), the Revised IPSS, the WHO Typed Prognos...
Guardado en:
Autores principales: | Yan Jiang, Su-Jun Gao, Benoit Soubise, Nathalie Douet-Guilbert, Zi-Ling Liu, Marie-Bérengère Troadec |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec8b25c4a03740d0ac190ec97f3a4263 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
<i>TP53</i> Combined Phenotype Score Is Associated with the Clinical Outcome of <i>TP53</i>-Mutated Myelodysplastic Syndromes
por: Mariko Yabe, et al.
Publicado: (2021) -
Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Edit Porpaczy, et al.
Publicado: (2021) -
<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
por: Ramya Thota, et al.
Publicado: (2021) -
<i>TP53</i> Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy
por: Humaira Noor, et al.
Publicado: (2021) -
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
por: Palacios-Campos,Adriana, et al.
Publicado: (2020)